Articles related to BREAST CANCER

Phase 3 ASCENT-04 data presented at ASCO 2026 showed improved PFS2 for sacituzumab govitecan plus pembrolizumab over chemotherapy plus pembrolizumab in previously untreated PD-L1-positive advanced triple-negative breast cancer, though an independent expert challenged PFS2 as a valid endpoint for establishing frontline standard-of-care status.

Nearly 18 million US women aged 45–64 were overdue for at least one recommended breast, cervical, or colorectal cancer screening, with colorectal cancer representing the largest unmet need in a 2024 BRFSS analysis of 36.2 million women.

A retrospective analysis of more than 840,000 patients with breast cancer found lower all-cause mortality and reduced recurrence risk among those with obesity or type 2 diabetes who received GLP-1 receptor agonists compared with similar patients who did not, though the study did not establish causation.

Retrospective analyses presented at SABCS 2025 associated GLP-1 receptor agonist use with weight loss, mortality, and recurrence signals in breast cancer cohorts, with effects on endocrine therapy tolerability also observed.

The FDA approved vepdegestrant for ESR1-mutated, ER-positive, HER2-negative advanced breast cancer after endocrine therapy progression, marking the first regulatory approval of a PROTAC drug.

ACP updated guidance recommends shared decision-making rather than routine biennial mammography for average-risk women aged 40 to 49, diverging from the USPSTF recommendation.